420 with CNW — German Pharmacies Now Have Access to Medical Cannabis from Australia
Extracts and flowers of cannabis that were produced in Australia by two different companies are now available to the public in the medical marijuana market of Germany for the first time. The flower is cultivated by (ANTG) or the Australian Natural Therapeutics Group, which is based in New South Wales. The flower was imported and batch released by Cannamedical, a company based in Cologne, Germany.
It is under the Indica forte brand, owned by Cannamedical, that the company sells cannabis flowers and extracts to medical cannabis pharmacies in Germany exclusively. The products’ batch-release certificate shows that the goods contain almost no CBD but feature nearly 22% THC and have an expiration date of June 2021.
David Henn, CEO of Cannamedical, told an online media outlet that the flower was not irradiated.
Additional extracts are produced by Little Green Pharma, a medical cannabis-producing company based in Western Australia. Little Green Pharma’s first commercial shipment of extracts was sent to Germany in November.
Little Green Pharma’s managing director Fleta Solomon says that the extracts were imported and batch released through Aphria subsidiary CC Pharma in Germany. The commodities were then sold to pharmacies by AMP Alternative Medical products and AlephSana, both of whom are German wholesalers.
The extracts that were traded under Little Green Pharma’s brand had two formulations: the LGP Classic Cannabis Extrakt 10:10, which has a balanced CBD and THC content, and the LGP Classic Cannabis Extrakt 20:5, which is high in THC.
These new products have allowed Australia to the list of other countries that are supplying full-spectrum extracts or flower to the medical marijuana market in Germany. Those countries include The Netherlands, Spain, Canada and Portugal. It is worth noting that some of Portugal’s product is originally grown in Uruguay. Additionally, other nations have sent shipments to Germany, but those shipments were for specific purposes and are not included on this list.
Many feel that it is great that patients who qualify to use medical marijuana products can now access a variety of such products sourced from different countries. In this way, one can select the most appropriate product for their needs.
A number of companies are engaged in the manufacture of pharmaceutical-grade cannabinoids. One such company is Green Hygienics Holdings Inc. (OTCQB: GRYN), which is seeking to revolutionize how cannabinoids are looked at in terms of bioavailability, pharmacokinetics and stability.
NOTE TO INVESTORS: The latest news and updates relating to Green Hygienics Holdings Inc. (OTCQB: GRYN) are available in the company’s newsroom at http://cnw.fm/GRYN
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Extracts and flowers of cannabis that were produced in Australia by two different companies are now available to the public in the medical marijuana market of Germany for the first time. The flower is cultivated by (ANTG) or the Australian Natural Therapeutics Group, which is based in New South Wales. The flower was imported and batch released by Cannamedical, a company based in Cologne, Germany.
It is under the Indica forte brand, owned by Cannamedical, that the company sells cannabis flowers and extracts to medical cannabis pharmacies in Germany exclusively. The products’ batch-release certificate shows that the goods contain almost no CBD but feature nearly 22% THC and have an expiration date of June 2021.
David Henn, CEO of Cannamedical, told an online media outlet that the flower was not irradiated.
Additional extracts are produced by Little Green Pharma, a medical cannabis-producing company based in Western Australia. Little Green Pharma’s first commercial shipment of extracts was sent to Germany in November.
Little Green Pharma’s managing director Fleta Solomon says that the extracts were imported and batch released through Aphria subsidiary CC Pharma in Germany. The commodities were then sold to pharmacies by AMP Alternative Medical products and AlephSana, both of whom are German wholesalers.
The extracts that were traded under Little Green Pharma’s brand had two formulations: the LGP Classic Cannabis Extrakt 10:10, which has a balanced CBD and THC content, and the LGP Classic Cannabis Extrakt 20:5, which is high in THC.
These new products have allowed Australia to the list of other countries that are supplying full-spectrum extracts or flower to the medical marijuana market in Germany. Those countries include The Netherlands, Spain, Canada and Portugal. It is worth noting that some of Portugal’s product is originally grown in Uruguay. Additionally, other nations have sent shipments to Germany, but those shipments were for specific purposes and are not included on this list.
Many feel that it is great that patients who qualify to use medical marijuana products can now access a variety of such products sourced from different countries. In this way, one can select the most appropriate product for their needs.
A number of companies are engaged in the manufacture of pharmaceutical-grade cannabinoids. One such company is Green Hygienics Holdings Inc. (OTCQB: GRYN), which is seeking to revolutionize how cannabinoids are looked at in terms of bioavailability, pharmacokinetics and stability.
NOTE TO INVESTORS: The latest news and updates relating to Green Hygienics Holdings Inc. (OTCQB: GRYN) are available in the company’s newsroom at http://cnw.fm/GRYN
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
